Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217823 | 0.82 | GPR119 (0.42) | L3MBTL1CYP17A1GPR119CYP24A1 | |
| SCHEMBL21367602 | 0.78 | L3MBTL1 (0.42) | L3MBTL1CYP17A1GPR119HTTNAMPT | |
| SCHEMBL30197806 | 0.78 | L3MBTL1 (0.40) | L3MBTL1CYP17A1GPR119HTTNAMPT | |
| SCHEMBL973988 | 0.77 | L3MBTL1 (0.41) | L3MBTL1CYP17A1GPR119NAMPTCYP24A1 | |
| SCHEMBL17093854 | 0.76 | IDO1 (0.43) | L3MBTL1CYP17A1CA12CA1CA2 | |
| SCHEMBL10077539 | 0.76 | L3MBTL1 (0.41) | L3MBTL1CYP17A1GPR119NAMPTCYP24A1 | |
| SCHEMBL1118621 | 0.75 | CYP17A1 (0.40) | L3MBTL1CYP17A1NAMPTBRD4PCSK9 | |
| SCHEMBL10716720 | 0.75 | CYP17A1 (0.40) | L3MBTL1CYP17A1CA1CA2 | |
| SCHEMBL22347134 | 0.75 | CYP17A1 (0.40) | L3MBTL1CYP17A1CA1CA2 | |
| SCHEMBL16272989 | 0.74 | CYP17A1 (0.36) | L3MBTL1CYP17A1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509941-B1 | N-ACYLATED HYDROXYLAMINE DERIVATIVES AND O-ACYLATED HYDROXYLAMINE DERIVATIVES | UNIV JOHNS HOPKINS (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | THE JOHNS HOPKINS UNIVERSITY | 2018-02-22 | — | — | US | disclosed |
| US-9458127-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160046570-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | THE JOHNS HOPKINS UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2015-07-16 | — | — | US | disclosed |
| US-9018411-B2 | Bis-acylated hydroxylamine derivatives | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2011071947-A2 | BIS-ACYLATED HYDROXYLAMINE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071951-A2 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | JOHNS HOPKINS UNIVERSITY (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-16 | — | — | US | disclosed |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | THE JOHNS HOPKINS UNIVERSITY | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235636-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | L3MBTL1 2461/4885CYP17A1 1584/4885GPR119 804/4885 |
| US-20150197502-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | L3MBTL1 844/4885CYP17A1 853/4885GPR119 518/4885 |
| US-20180050985-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, NOS2 | L3MBTL1 2494/4885CYP17A1 1545/4885GPR119 800/4885 |
| US-20160046570-A1 | N-ACYLOXYSULFONAMIDE AND N-HYDROXY-N-ACYLSULFONAMIDE DERIVATIVES | TNNI3, TNNT2, TNNC1 | L3MBTL1 2461/4885CYP17A1 1584/4885GPR119 804/4885 |
| US-20110144067-A1 | N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives | TNNI3, TNNT2, TNNC1 | L3MBTL1 2461/4885CYP17A1 1584/4885GPR119 804/4885 |
| US-20110136827-A1 | Bis-Acylated Hydroxylamine Derivatives | CPT1A, TNNI3, NOS2 | L3MBTL1 844/4885CYP17A1 853/4885GPR119 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.